# Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Expanding Rare Disease Portfolio

*2026-04-07 12:03 UTC · Business · 1 min read*

> Neurocrine Biosciences announced a $2.9 billion cash deal to buy Soleno Therapeutics, gaining VYKAT XR, the first-in-class treatment for Prader-Willi syndrome.

Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $53 per share in cash, valuing the deal at approximately $2.9 billion. The acquisition gives Neurocrine access to VYKAT XR (diazoxide choline), a first-in-class therapy approved by the FDA in 2025 for treating hyperphagia — the defining feature of Prader-Willi syndrome, a rare genetic disorder affecting roughly 10,000 patients in the U.S.

VYKAT XR generated $190 million in revenue during its first year on the market, with intellectual property protection extending through the mid-2040s. The offer represents a 34% premium over Soleno's closing price on April 2 and a 51% premium to its 30-day volume-weighted average. Soleno shares surged nearly 40% on the news.

Neurocrine CEO Kyle Gano called the deal a step toward "delivering life-changing treatments while accelerating revenue growth and portfolio diversification." The transaction is expected to close within 90 days pending regulatory approval.

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio-302734531.html)
- [finance.yahoo.com](https://finance.yahoo.com/sectors/healthcare/articles/neurocrine-buy-soleno-therapeutics-2-110701181.html)
- [bloomberg.com](https://www.bloomberg.com/news/articles/2026-04-06/neurocrine-to-buy-soleno-therapeutics-for-2-9-billion)

---
TechTools News · https://techtools.cz/tools/news/article/1334-neurocrine-biosciences-to-acquire-soleno-therapeutics-for-2-9-billion-expanding
Česká verze: https://techtools.cz/tools/news/clanek/1392-neurocrine-biosciences-kupuje-soleno-therapeutics-za-2-9-miliardy-dolaru-a
